STOCK TITAN

Durect Corp - DRRX STOCK NEWS

Welcome to our dedicated page for Durect news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on Durect stock.

DURECT Corporation (Nasdaq: DRRX) is a specialized biopharmaceutical company focused on the research, development, and manufacturing of innovative pharmaceutical products. With expertise in drug discovery, delivery, and development, DURECT dedicates its efforts to creating therapies aimed at pain management, acute organ injury, and metabolic diseases. Their proprietary technologies, including oral, transdermal, and injectable depot delivery systems, enhance clinical and commercial attributes such as abuse deterrence, convenience, adherence, efficacy, and safety for both small molecule and biologic drugs.

One of DURECT’s key assets is larsucosterol, an epigenetic modulator currently in Phase 3 clinical trials for the treatment of severe alcohol-associated hepatitis (AH). This promising candidate has received both Fast Track and Breakthrough Therapy designations from the FDA. The company's Phase 2b AHFIRM trial demonstrated significant potential in reducing mortality among AH patients, paving the way for further research and development.

Another noteworthy product is POSIMIR®, an FDA-approved non-opioid analgesic for post-surgical pain management, which utilizes DURECT’s SABER® platform technology. It is exclusively licensed to Innocoll Pharmaceuticals for distribution in the United States.

DURECT also markets ALZET® osmotic pumps, widely used in preclinical research for continuous drug delivery in laboratory animals. A collaboration with Charles River Laboratories aims to further expand the reach of this product line within the pharmaceutical and academic sectors.

Financially, DURECT continues to advance its pipeline with strategic capital management, ensuring the sustainability of its operations while actively seeking regulatory approvals for its drug candidates. Their latest developments include quarterly financial reports, conference calls with stakeholders, and presentations at major medical conferences, showcasing their commitment to transparency and progress.

For more information, visit www.durect.com and follow the company on X (formerly Twitter) at https://x.com/DURECTCorp.

Rhea-AI Summary

DURECT Corporation (NASDAQ: DRRX) announced the appointment of Gail Maderis as the new Chair of the Board, effective March 17, 2023. She takes over from David Hoffmann, who will retire on June 21, 2023. Maderis has been a board member since January 2021, contributing to audit and compensation committees. The leadership change comes at a pivotal time for DURECT as it anticipates top-line data from its AHFIRM trial later this year. Maderis brings extensive biopharmaceutical experience, having previously led various organizations and currently serving as President and CEO of Antiva Biosciences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
management
-
Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) announced that CEO Dr. James Brown and management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The discussion will be accessible from 2:00 to 2:20 PM Eastern Time and will cover DURECT's innovative therapies, including larsucosterol and POSIMIR. Larsucosterol is in clinical development for alcohol-associated hepatitis, with FDA Fast Track Designation. A webcast link for the presentation will be available on DURECT's website, with a replay available for 90 days. The press release includes forward-looking statements regarding future trials and commercialization efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
-
Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) reported financial results for Q4 and FY 2022, with total revenues of $3.3 million for Q4, down from $7.3 million a year prior. The net loss increased to $10.5 million compared to $7.0 million in Q4 2021. For the full year, revenues were $19.3 million with a net loss of $35.3 million. Cash holdings decreased to $43.6 million from $70.0 million year-over-year. The company is on track to complete enrollment in the AHFIRM trial in Q2 2023, with topline data expected in the latter half of the year, which may allow for potential FDA discussions regarding a New Drug Application (NDA) for Larsucosterol.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
Rhea-AI Summary

DURECT Corporation (NASDAQ: DRRX) has announced it will report its fourth quarter and full year 2022 financial results on March 7, 2023, after market closure. The company is set to host a conference call at 4:30 PM ET to discuss the results. DURECT is known for its advancements in treatment for acute organ injury and chronic liver diseases, particularly its lead drug candidate Larsucosterol (DUR-928), currently in clinical development for alcohol-associated hepatitis with FDA Fast Track Designation. The company also holds an FDA-approved product, POSIMIR, licensed to Innocoll Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
-
Rhea-AI Summary

DURECT Corporation (NASDAQ: DRRX) announced a registered direct offering of common stock and warrants, aiming to raise approximately $10 million. The offering includes 1,700,000 shares of common stock and pre-funded warrants for 300,000 shares, priced at $5.00 and $4.99999 respectively. Accompanying warrants will allow the purchase of up to 2,000,000 shares at $5.00 each, with pre-funded warrants having no expiration. The proceeds will be used for general corporate purposes, including clinical trials and research. Closing is expected on February 8, 2023, pending customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
-
Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) announced a 1-for-10 reverse stock split effective December 5, 2022, aimed at meeting Nasdaq's minimum bid price requirement of $1.00. The decision follows stockholder approval during a Special Meeting held on November 22, 2022. Post-split, approximately 22.8 million shares will be outstanding, and the authorized shares will decrease from 600 million to 150 million. This reverse split is expected to attract more institutional investors while maintaining existing ownership percentages for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.87%
Tags
none
Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) reported Q3 2022 revenues of $12.0 million with a net loss of $2.5 million, an improvement from $2.2 million in revenues and a net loss of $10 million during the same period in 2021. The company is optimistic about completing its AHFIRM trial enrollment by Q2 2023, ahead of schedule, as they have surpassed 200 patients enrolled. DURECT received $10 million in milestone payments related to the launch of POSIMIR by Innocoll and a new patent extending coverage until 2041.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
-
Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) will report its third quarter 2022 financial results on November 2, 2022, at 4:30 PM ET, followed by a conference call. The company is focused on innovative therapies for acute organ injury and chronic liver diseases, with its lead candidate, larsucosterol (DUR-928), in development for conditions like alcohol-associated hepatitis, which has FDA Fast Track Designation. POSIMIR®, an FDA-approved non-opioid analgesic, is licensed to Innocoll Pharmaceuticals. Investors can access the conference details via a webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
-
Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) has surpassed 200 patient enrollments in its Phase 2b AHFIRM trial, aimed at evaluating larsucosterol for treating severe alcohol-associated hepatitis (AH). With a target of 300 patients, completion is anticipated by Q2 2023. The FDA has granted Fast Track Designation for larsucosterol, highlighting the urgent need for effective AH treatments. The trial's primary outcome will assess the 90-day incidence of mortality or liver transplantation, compared to placebo treatment. Topline results are expected in the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
Rhea-AI Summary

POSIMIR®, a new treatment for post-surgical pain, is now available in the U.S. following its launch by Innocoll Pharmaceuticals in collaboration with DURECT Corporation (Nasdaq: DRRX). This FDA-approved, non-opioid sustained-release local analgesic is specifically designed for adults after arthroscopic subacromial decompression surgery. DURECT recently received milestone payments totaling $10 million for the patent issuance and first sale of POSIMIR, and stands to earn additional royalties and milestone payments of up to $122 million as sales progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none

FAQ

What is the current stock price of Durect (DRRX)?

The current stock price of Durect (DRRX) is $0.97 as of December 24, 2024.

What is the market cap of Durect (DRRX)?

The market cap of Durect (DRRX) is approximately 30.1M.

What is DURECT Corporation's primary focus?

DURECT Corporation specializes in drug discovery, delivery, and development, primarily targeting pain management, acute organ injury, and metabolic diseases.

What are DURECT's key products?

Key products include larsucosterol, POSIMIR®, and ALZET® osmotic pumps.

What is larsucosterol?

Larsucosterol is an epigenetic modulator currently in Phase 3 trials for severe alcohol-associated hepatitis (AH).

Has larsucosterol received any special designations from the FDA?

Yes, it has received both Fast Track and Breakthrough Therapy designations.

What is POSIMIR®?

POSIMIR® is an FDA-approved non-opioid analgesic for post-surgical pain management, utilizing DURECT’s SABER® platform technology.

Who distributes POSIMIR® in the United States?

POSIMIR® is exclusively licensed to Innocoll Pharmaceuticals for distribution in the United States.

What are ALZET® osmotic pumps?

ALZET® osmotic pumps are miniature implantable pumps used for continuous drug delivery in laboratory animals, widely utilized in preclinical research.

What recent financial updates has DURECT provided?

DURECT regularly reports financial results, hosts conference calls, and provides corporate updates to stakeholders.

How does DURECT engage with the scientific community?

DURECT participates in major medical conferences and collaborates with partners like Charles River Laboratories to broaden the reach of their products.

Where can I find more information about DURECT Corporation?

For more information, visit www.durect.com and follow the company on X (formerly Twitter) at https://x.com/DURECTCorp.

Durect Corp

Nasdaq:DRRX

DRRX Rankings

DRRX Stock Data

30.11M
28.16M
5.79%
23%
3.15%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CUPERTINO